{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T20:32:45Z","timestamp":1793219565129,"version":"4.5.0"},"reference-count":131,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T00:00:00Z","timestamp":1790812800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T00:00:00Z","timestamp":1783468800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Revue Neurologique"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1016\/j.neurol.2026.06.004","type":"journal-article","created":{"date-parts":[[2026,7,21]],"date-time":"2026-07-21T11:34:40Z","timestamp":1784633680000},"page":"771-783","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder"],"prefix":"10.1016","volume":"182","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-5537-9093","authenticated-orcid":false,"given":"L.","family":"Giorgi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Marignier","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1986-7945","authenticated-orcid":false,"given":"J.","family":"Pique","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H.","family":"Maurey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Papeix","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3386-6308","authenticated-orcid":false,"given":"J.","family":"Ciron","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3683-5582","authenticated-orcid":false,"given":"N.","family":"Collongues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2105-2518","authenticated-orcid":false,"given":"E.","family":"Cheuret","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4029-2012","authenticated-orcid":false,"given":"H.","family":"Zephir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5710-7376","authenticated-orcid":false,"given":"P.","family":"Meyer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Vukusic","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Doret-Dion","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-T.","family":"AbiWarde","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Nguyen The Tich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2459-2480","authenticated-orcid":false,"given":"B.","family":"Bourre","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"Audoin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.-C.","family":"Pouget","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"Yver","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C.","family":"Lattaud","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1452-1398","authenticated-orcid":false,"given":"C.","family":"Froment Tilikete","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J.","family":"De S\u00e8ze","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.-C.","family":"Debroise","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Gel\u00e9","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Mamoudjy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5323-911X","authenticated-orcid":false,"given":"P.","family":"Cleuziou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7699-0328","authenticated-orcid":false,"given":"E.","family":"Maillart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Deiva","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0005","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.neurol.2025.04.012","article-title":"French guidelines for the diagnosis and management of MOG antibody-associated disease","volume":"181","author":"Giorgi","year":"2025","journal-title":"Rev Neurol (Paris)"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0010","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1016\/S1474-4422(07)70216-8","article-title":"The spectrum of neuromyelitis optica","volume":"6","author":"Wingerchuk","year":"2007","journal-title":"Lancet Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0015","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1212\/WNL.0000000000001729","article-title":"International consensus diagnostic criteria for neuromyelitis optica spectrum disorders","volume":"85","author":"Wingerchuk","year":"2015","journal-title":"Neurology"},{"issue":"23","key":"10.1016\/j.neurol.2026.06.004_bib0020","doi-asserted-by":"crossref","first-page":"2197","DOI":"10.1212\/01.wnl.0000303817.82134.da","article-title":"NMO-IgG predicts the outcome of recurrent optic neuritis","volume":"70","author":"Matiello","year":"2008","journal-title":"Neurology"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0025","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1055\/s-0043-1761432","article-title":"Neuromyelitis optica spectrum disorders: a review with a focus on children and adolescents","volume":"81","author":"Paolilo","year":"2023","journal-title":"Arq Neuropsiquiatr"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0030","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1212\/WNL.53.5.1107","article-title":"The clinical course of neuromyelitis optica (Devic's syndrome)","volume":"53","author":"Wingerchuk","year":"1999","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0035","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1007\/s00415-016-8155-7","article-title":"Optic neuritis: a 5-year follow-up study of Chinese patients based on aquaporin-4 antibody status and ages","volume":"263","author":"Zhou","year":"2016","journal-title":"J Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2026.06.004_bib0040","doi-asserted-by":"crossref","first-page":"2130","DOI":"10.1007\/s00415-017-8606-9","article-title":"Prognostic factors and disease course in aquaporin-4 antibody-positive Chinese patients with acute optic neuritis","volume":"264","author":"Kang","year":"2017","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0045","doi-asserted-by":"crossref","first-page":"e837","DOI":"10.1212\/NXI.0000000000000837","article-title":"Treatment and outcome of aquaporin-4 antibody-positive NMOSD: a multinational pediatric study","volume":"7","author":"Paolilo","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0050","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1136\/jnnp-2021-327206","article-title":"Early predictors of disability of paediatric-onset AQP4-IgG-seropositive neuromyelitis optica spectrum disorders","volume":"93","author":"Camera","year":"2022","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1111\/cei.13630","article-title":"Magnetic resonance imaging in neuromyelitis optica spectrum disorder","volume":"206","author":"Clarke","year":"2021","journal-title":"Clin Exp Immunol"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0060","doi-asserted-by":"crossref","first-page":"1031","DOI":"10.2214\/AJR.20.24061","article-title":"MOGAD: how it differs from and resembles other neuroinflammatory disorders","volume":"216","author":"Shahriari","year":"2021","journal-title":"AJR Am J Roentgenol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0065","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/archneur.63.3.390","article-title":"Brain abnormalities in neuromyelitis optica","volume":"63","author":"Pittock","year":"2006","journal-title":"Arch Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0070","doi-asserted-by":"crossref","first-page":"102428","DOI":"10.1016\/j.msard.2020.102428","article-title":"Latin American consensus recommendations for management and treatment of neuromyelitis optica spectrum disorders in clinical practice","volume":"45","author":"Carnero Contentti","year":"2020","journal-title":"Mult Scler Relat Disord"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2026.06.004_bib0075","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.jns.2015.05.013","article-title":"Longitudinally extensive optic neuritis as an MRI biomarker distinguishes neuromyelitis optica from multiple sclerosis","volume":"355","author":"Mealy","year":"2015","journal-title":"J Neurol Sci"},{"issue":"1-2","key":"10.1016\/j.neurol.2026.06.004_bib0080","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/j.jns.2014.07.049","article-title":"Longitudinally extensive optic neuritis in neuromyelitis optica spectrum disorder","volume":"345","author":"Pula","year":"2014","journal-title":"J Neurol Sci"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0085","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1097\/WNO.0b013e318254c62d","article-title":"Magnetic resonance imaging of optic neuritis in patients with neuromyelitis optica versus multiple sclerosis","volume":"32","author":"Khanna","year":"2012","journal-title":"J Neuroophthalmol"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0090","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1007\/s10072-014-1635-6","article-title":"First-ever optic neuritis: distinguishing subsequent neuromyelitis optica from multiple sclerosis","volume":"35","author":"Lim","year":"2014","journal-title":"Neurol Sci"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0095","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.neurol.2013.04.008","article-title":"[Nosology and etiologies of acute longitudinally extensive transverse myelitis]","volume":"170","author":"Collongues","year":"2014","journal-title":"Rev Neurol (Paris)"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.004_bib0100","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1001\/archneurol.2012.112","article-title":"Painful tonic spasm in neuromyelitis optica: incidence, diagnostic utility, and clinical characteristics","volume":"69","author":"Kim","year":"2012","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0105","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1038\/nrneurol.2014.129","article-title":"Pain in neuromyelitis optica\u00a0\u2013\u00a0prevalence, pathogenesis and therapy","volume":"10","author":"Bradl","year":"2014","journal-title":"Nat Rev Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0110","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1007\/s10072-016-2523-z","article-title":"Intractable pruritus in neuromyelitis optica","volume":"37","author":"Xiao","year":"2016","journal-title":"Neurol Sci"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0115","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/S1474-4422(18)30460-5","article-title":"Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"18","author":"Ciccarelli","year":"2019","journal-title":"Lancet Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0120","doi-asserted-by":"crossref","first-page":"710","DOI":"10.1177\/1352458514551454","article-title":"Idiopathic aquaporin-4 antibody negative longitudinally extensive transverse myelitis","volume":"21","author":"Hyun","year":"2015","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0125","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1038\/nrneurol.2018.14","article-title":"The current role of MRI in differentiating multiple sclerosis from its imaging mimics","volume":"14","author":"Geraldes","year":"2018","journal-title":"Nat Rev Neurol"},{"issue":"8-9","key":"10.1016\/j.neurol.2026.06.004_bib0130","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1177\/08830738221103085","article-title":"A comparison of pediatric- and adult-onset aquaporin-4 immunoglobulin G-positive neuromyelitis optica spectrum disorder: a review of clinical and radiographic characteristics","volume":"37","author":"Tarhan","year":"2022","journal-title":"J Child Neurol"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0135","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1001\/jamaneurol.2014.2137","article-title":"Short myelitis lesions in aquaporin-4-IgG-positive neuromyelitis optica spectrum disorders","volume":"72","author":"Flanagan","year":"2015","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0140","doi-asserted-by":"crossref","first-page":"302","DOI":"10.1177\/1352458515591069","article-title":"Differentiating neuromyelitis optica from other causes of longitudinally extensive transverse myelitis on spinal magnetic resonance imaging","volume":"22","author":"Pekcevik","year":"2016","journal-title":"Mult Scler"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0145","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1177\/1352458520906995","article-title":"Atypical myelitis in patients with multiple sclerosis: characterization and comparison with typical multiple sclerosis and neuromyelitis optica spectrum disorders","volume":"27","author":"Bigaut","year":"2021","journal-title":"Mult Scler"},{"issue":"1\u20132","key":"10.1016\/j.neurol.2026.06.004_bib0150","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.jns.2010.02.026","article-title":"Characteristic linear lesions and longitudinally extensive spinal cord lesions in Chinese patients with neuromyelitis optica","volume":"293","author":"Lu","year":"2010","journal-title":"J Neurol Sci"},{"key":"10.1016\/j.neurol.2026.06.004_bib0155","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1471-2377-13-33","article-title":"Modifications of longitudinally extensive transverse myelitis and brainstem lesions in the course of neuromyelitis optica (NMO): a population-based, descriptive study","volume":"13","author":"Asgari","year":"2013","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0160","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.jns.2016.11.035","article-title":"The characteristics of spinal imaging in different types of demyelinating diseases","volume":"372","author":"Dumrikarnlert","year":"2017","journal-title":"J Neurol Sci"},{"issue":"17","key":"10.1016\/j.neurol.2026.06.004_bib0165","doi-asserted-by":"crossref","first-page":"e1642","DOI":"10.1212\/WNL.0000000000006392","article-title":"Area postrema syndrome: frequency, criteria, and severity in AQP4-IgG-positive NMOSD","volume":"91","author":"Shosha","year":"2018","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0170","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1001\/jamaneurol.2016.5441","article-title":"Association of extension of cervical cord lesion and area postrema syndrome with neuromyelitis optica spectrum disorder","volume":"74","author":"Dubey","year":"2017","journal-title":"JAMA Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0175","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.pediatrneurol.2023.12.010","article-title":"The etiology and outcome of area postrema syndrome in childhood: two cases and a literature review","volume":"152","author":"Tomari","year":"2024","journal-title":"Pediatr Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0180","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1177\/1352458510391690","article-title":"Wall-eyed bilateral internuclear ophthalmoplegia (WEBINO) syndrome in a patient with neuromyelitis optica spectrum disorder and anti-aquaporin-4 antibody","volume":"17","author":"Shinoda","year":"2011","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0185","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1177\/1352458513507822","article-title":"Brainstem manifestations in neuromyelitis optica: a multicenter study of 258 patients","volume":"20","author":"Kremer","year":"2014","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0190","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1007\/s00415-014-7537-y","article-title":"Syndrome of inappropriate antidiuretic hormone secretion in patients with aquaporin-4 antibody","volume":"262","author":"Pu","year":"2015","journal-title":"J Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0195","doi-asserted-by":"crossref","first-page":"287","DOI":"10.1007\/s00415-009-0139-4","article-title":"Narcolepsy as an initial manifestation of neuromyelitis optica with anti-aquaporin-4 antibody","volume":"256","author":"Baba","year":"2009","journal-title":"J Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0200","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1191\/1352458505ms1200cr","article-title":"Neuromyelitis optica with hypothalamic involvement","volume":"11","author":"Poppe","year":"2005","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0205","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1177\/1352458517726593","article-title":"Endocrinopathies in paediatric-onset neuromyelitis optica spectrum disorder with aquaporin 4 (AQP4) antibody","volume":"24","author":"Hacohen","year":"2018","journal-title":"Mult Scler"},{"issue":"10","key":"10.1016\/j.neurol.2026.06.004_bib0210","doi-asserted-by":"crossref","first-page":"2459","DOI":"10.21037\/tp-21-370","article-title":"Identification of the clinical and neuroimaging characteristics in children with neuromyelitis optica spectrum disorders: a case series","volume":"10","author":"Zhang","year":"2021","journal-title":"Transl Pediatr"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0215","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1136\/jnnp-2014-308550","article-title":"Paediatric neuromyelitis optica: clinical, MRI of the brain and prognostic features","volume":"86","author":"Absoud","year":"2015","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0220","doi-asserted-by":"crossref","first-page":"663","DOI":"10.1007\/s00415-012-6755-4","article-title":"Steroid-responsive hearing impairment in NMO-IgG\/aquaporin-4-antibody-positive neuromyelitis optica","volume":"260","author":"Jarius","year":"2013","journal-title":"J Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0225","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/WNO.0b013e31821d549b","article-title":"Ocular oscillations in the neuromyelitis optica spectrum","volume":"31","author":"Hage","year":"2011","journal-title":"J Neuroophthalmol"},{"issue":"17","key":"10.1016\/j.neurol.2026.06.004_bib0230","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1212\/WNL.0b013e3182703ff7","article-title":"Two cases of lumbosacral myeloradiculitis with anti-aquaporin-4 antibody","volume":"79","author":"Takai","year":"2012","journal-title":"Neurology"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.004_bib0235","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1212\/01.wnl.0000343001.36493.ae","article-title":"Posterior reversible encephalopathy syndrome in neuromyelitis optica spectrum disorders","volume":"72","author":"Maga\u00f1a","year":"2009","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.06.004_bib0240","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.wneu.2019.05.177","article-title":"Acute hydrocephalus resulting from neuromyelitis optica: a case report and review of the literature","volume":"129","author":"Close","year":"2019","journal-title":"World Neurosurg"},{"key":"10.1016\/j.neurol.2026.06.004_bib0245","doi-asserted-by":"crossref","first-page":"577228","DOI":"10.1016\/j.jneuroim.2020.577228","article-title":"Is transient hyperCKemia a new feature of neuromyelitis optica spectrum disorders? A retrospective study in 439 patients","volume":"343","author":"Sun","year":"2020","journal-title":"J Neuroimmunol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0250","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.msard.2017.10.003","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: what do we know?","volume":"18","author":"Eizaguirre","year":"2017","journal-title":"Mult Scler Relat Disord"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0255","doi-asserted-by":"crossref","first-page":"e33878","DOI":"10.1371\/journal.pone.0033878","article-title":"White matter atrophy and cognitive dysfunctions in neuromyelitis optica","volume":"7","author":"Blanc","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.neurol.2026.06.004_bib0260","doi-asserted-by":"crossref","first-page":"608","DOI":"10.3389\/fneur.2019.00608","article-title":"Cognitive impairment in neuromyelitis optica spectrum disorders: a review of clinical and neuroradiological features","volume":"10","author":"Oertel","year":"2019","journal-title":"Front Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0265","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1084\/jem.20050304","article-title":"IgG marker of optic-spinal multiple sclerosis binds to the aquaporin-4 water channel","volume":"202","author":"Lennon","year":"2005","journal-title":"J Exp Med"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0270","article-title":"Diagnostic value of aquaporin-4-IgG live cell based assay in neuromyelitis optica spectrum disorders","volume":"7","author":"Redenbaugh","year":"2021","journal-title":"Mult Scler J - Exp Transl Clin"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0275","doi-asserted-by":"crossref","first-page":"1005","DOI":"10.1136\/jnnp-2015-312601","article-title":"Multicentre comparison of a diagnostic assay: aquaporin-4 antibodies in neuromyelitis optica","volume":"87","author":"Waters","year":"2016","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0280","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1111\/cen3.12107","article-title":"Evaluation of aquaporin-4 antibody assays","volume":"5","author":"Waters","year":"2014","journal-title":"Clin Exp Neuroimmunol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0285","doi-asserted-by":"crossref","first-page":"e308","DOI":"10.1212\/WNL.0000000000201465","article-title":"Differentiating multiple sclerosis from AQP4-neuromyelitis optica spectrum disorder and MOG-antibody disease with imaging","volume":"100","author":"Cortese","year":"2023","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0290","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1212\/01.wnl.0000284600.80782.d5","article-title":"Neuromyelitis optica-IgG in childhood inflammatory demyelinating CNS disorders","volume":"70","author":"Banwell","year":"2008","journal-title":"Neurology"},{"key":"10.1016\/j.neurol.2026.06.004_bib0295","doi-asserted-by":"crossref","first-page":"1536853","DOI":"10.3389\/fimmu.2025.1536853","article-title":"Comparison of the clinical and laboratory characteristics of neuromyelitis optica spectrum disorder with or without cerebrospinal fluid oligoclonal bands: a cohort with 36-month follow-up","volume":"16","author":"Yang","year":"2025","journal-title":"Front Immunol"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0300","doi-asserted-by":"crossref","first-page":"3341","DOI":"10.1007\/s00415-023-11634-0","article-title":"Update on the diagnosis and treatment of neuromyelits optica spectrum disorders (NMOSD)\u00a0\u2013\u00a0revised recommendations of the Neuromyelitis Optica Study Group (NEMOS). Part I: diagnosis and differential diagnosis","volume":"270","author":"Jarius","year":"2023","journal-title":"J Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0305","doi-asserted-by":"crossref","first-page":"757","DOI":"10.1136\/jnnp-2022-330412","article-title":"Serum neurofilament light chain levels at attack predict post-attack disability worsening and are mitigated by inebilizumab: analysis of four potential biomarkers in neuromyelitis optica spectrum disorder","volume":"94","author":"Aktas","year":"2023","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0310","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1002\/ana.26067","article-title":"Serum glial fibrillary acidic protein: a neuromyelitis optica spectrum disorder biomarker","volume":"89","author":"Aktas","year":"2021","journal-title":"Ann Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0315","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1007\/s10072-023-07277-8","article-title":"Neurofilament light chain as a biomarker in neuromyelitis optica spectrum disorder: a comprehensive review and integrated analysis with glial fibrillary acidic protein","volume":"45","author":"Kim","year":"2024","journal-title":"Neurol Sci"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0320","doi-asserted-by":"crossref","first-page":"927","DOI":"10.1136\/jnnp-2018-317969","article-title":"CSF cytokine profile in MOG-IgG+ neurological disease is similar to AQP4-IgG+ NMOSD but distinct from MS: a cross-sectional study and potential therapeutic implications","volume":"89","author":"Kaneko","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0325","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1159\/000494976","article-title":"Cytokines and tissue damage biomarkers in first-onset neuromyelitis optica spectrum disorders: significance of interleukin-6","volume":"25","author":"Wei","year":"2018","journal-title":"Neuroimmunomodulation"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0330","doi-asserted-by":"crossref","first-page":"e841","DOI":"10.1212\/NXI.0000000000000841","article-title":"Interleukin-6 in neuromyelitis optica spectrum disorder pathophysiology","volume":"7","author":"Fujihara","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0335","doi-asserted-by":"crossref","first-page":"e200386","DOI":"10.1212\/NXI.0000000000200386","article-title":"Diagnostic utility of kappa free light chain index in adults with inaugural optic neuritis","volume":"12","author":"Demortiere","year":"2025","journal-title":"Neurol Neuroimmunol Neuroinflamm"},{"issue":"11\u201312","key":"10.1016\/j.neurol.2026.06.004_bib0340","doi-asserted-by":"crossref","first-page":"1436","DOI":"10.1177\/13524585241274034","article-title":"The kappa free light chains index is an accurate diagnostic biomarker for paediatric multiple sclerosis","volume":"30","author":"Sarthou","year":"2024","journal-title":"Mult Scler"},{"issue":"8","key":"10.1016\/j.neurol.2026.06.004_bib0345","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1177\/1352458507077189","article-title":"Low-dose corticosteroids reduce relapses in neuromyelitis optica: a retrospective analysis","volume":"13","author":"Watanabe","year":"2007","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0350","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1177\/1352458508100837","article-title":"Plasma exchange in severe spinal attacks associated with neuromyelitis optica spectrum disorder","volume":"15","author":"Bonnan","year":"2009","journal-title":"Mult Scler"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0355","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1001\/archophthalmol.2012.1126","article-title":"Treatment of optic neuritis by plasma exchange (add-on) in neuromyelitis optica","volume":"130","author":"Merle","year":"2012","journal-title":"Arch Ophthalmol"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0360","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/ana.24554","article-title":"Neuromyelitis optica: evaluation of 871 attacks and 1153 treatment courses","volume":"79","author":"Kleiter","year":"2016","journal-title":"Ann Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0365","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1136\/jnnp-2017-316286","article-title":"Short delay to initiate plasma exchange is the strongest predictor of outcome in severe attacks of NMO spectrum disorders","volume":"89","author":"Bonnan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0370","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S1474-4422(20)30066-1","article-title":"Safety and efficacy of rituximab in neuromyelitis optica spectrum disorders (RIN-1 study): a multicentre, randomised, double-blind, placebo-controlled trial","volume":"19","author":"Tahara","year":"2020","journal-title":"Lancet Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0375","doi-asserted-by":"crossref","first-page":"102843","DOI":"10.1016\/j.msard.2021.102843","article-title":"Efficacy of rituximab in the treatment of neuromyelitis optica spectrum disorders: an update systematic review and meta-analysis","volume":"50","author":"Wang","year":"2021","journal-title":"Mult Scler Relat Disord"},{"issue":"10","key":"10.1016\/j.neurol.2026.06.004_bib0380","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1002\/acn3.51451","article-title":"A meta-analysis comparing first-line immunosuppressants in neuromyelitis optica","volume":"8","author":"Giovannelli","year":"2021","journal-title":"Ann Clin Transl Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0385","doi-asserted-by":"crossref","DOI":"10.1177\/17562864211056710","article-title":"Adverse events of rituximab in neuromyelitis optica spectrum disorder: a systematic review and meta-analysis","volume":"14","author":"Wang","year":"2021","journal-title":"Ther Adv Neurol Disord"},{"issue":"11","key":"10.1016\/j.neurol.2026.06.004_bib0390","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1001\/jamaneurol.2016.1637","article-title":"Efficacy and safety of rituximab therapy in neuromyelitis optica spectrum disorders: a systematic review and meta-analysis","volume":"73","author":"Damato","year":"2016","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0395","doi-asserted-by":"crossref","first-page":"e977","DOI":"10.1212\/NXI.0000000000000977","article-title":"Rituximab-induced hypogammaglobulinemia and infections in AQP4 and MOG antibody-associated diseases","volume":"8","author":"Avouac","year":"2021","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0400","doi-asserted-by":"crossref","first-page":"1477","DOI":"10.1002\/acn3.51136","article-title":"Serious safety events in rituximab-treated multiple sclerosis and related disorders","volume":"7","author":"Vollmer","year":"2020","journal-title":"Ann Clin Transl Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2026.06.004_bib0405","doi-asserted-by":"crossref","first-page":"e2504","DOI":"10.1212\/WNL.0000000000201260","article-title":"Long-term effectiveness and safety of rituximab in neuromyelitis optica spectrum disorder and MOG antibody disease","volume":"99","author":"Barreras","year":"2022","journal-title":"Neurology"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0410","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1001\/jamaneurol.2015.1276","article-title":"Treatment outcomes with rituximab in 100 patients with neuromyelitis optica: influence of FCGR3A polymorphisms on the therapeutic response to rituximab","volume":"72","author":"Kim","year":"2015","journal-title":"JAMA Neurol"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0415","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1136\/jnnp-2018-318465","article-title":"Less frequent rituximab retreatment maintains remission of neuromyelitis optica spectrum disorder, following long-term rituximab treatment","volume":"90","author":"Kim","year":"2019","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0420","doi-asserted-by":"crossref","first-page":"e1179","DOI":"10.1212\/NXI.0000000000001179","article-title":"Rituximab-induced hypogammaglobulinemia and risk of infection in neuromyelitis optica spectrum disorders: a 14-year real-life experience","volume":"9","author":"Kim","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0425","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1136\/jnnp-2017-316880","article-title":"Clinical course, therapeutic responses and outcomes in relapsing MOG antibody-associated demyelination","volume":"89","author":"Ramanathan","year":"2018","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0430","doi-asserted-by":"crossref","first-page":"e683","DOI":"10.1212\/NXI.0000000000000683","article-title":"Dramatic efficacy of ofatumumab in refractory pediatric-onset AQP4-IgG neuromyelitis optica spectrum disorder","volume":"7","author":"Maillart","year":"2020","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"10206","key":"10.1016\/j.neurol.2026.06.004_bib0435","doi-asserted-by":"crossref","first-page":"1352","DOI":"10.1016\/S0140-6736(19)31817-3","article-title":"Inebilizumab for the treatment of neuromyelitis optica spectrum disorder (N-MOmentum): a double-blind, randomised placebo-controlled phase 2\/3 trial","volume":"394","author":"Cree","year":"2019","journal-title":"Lancet"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0440","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1177\/13524585211047223","article-title":"Long-term efficacy and safety of inebilizumab in neuromyelitis optica spectrum disorder: analysis of aquaporin-4-immunoglobulin G-seropositive participants taking inebilizumab for\u00a0\u2265\u00a04\u00a0years in the N-MOmentum trial","volume":"28","author":"Rensel","year":"2022","journal-title":"Mult Scler"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0445","doi-asserted-by":"crossref","first-page":"827","DOI":"10.3109\/s10165-012-0715-9","article-title":"Clinical improvement in a patient with neuromyelitis optica following therapy with the anti-IL-6 receptor monoclonal antibody tocilizumab","volume":"23","author":"Araki","year":"2013","journal-title":"Mod Rheumatol"},{"issue":"15","key":"10.1016\/j.neurol.2026.06.004_bib0450","doi-asserted-by":"crossref","first-page":"1302","DOI":"10.1212\/WNL.0000000000000317","article-title":"Efficacy of the anti-IL-6 receptor antibody tocilizumab in neuromyelitis optica: a pilot study","volume":"82","author":"Araki","year":"2014","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0455","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1001\/jamaneurol.2013.1246","article-title":"Interleukin 6 receptor blockade in patients with neuromyelitis optica nonresponsive to anti-CD20 therapy","volume":"70","author":"Ayzenberg","year":"2013","journal-title":"JAMA Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0460","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1001\/jamaneurol.2013.668","article-title":"Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses","volume":"70","author":"Kieseier","year":"2013","journal-title":"JAMA Neurol"},{"issue":"2","key":"10.1016\/j.neurol.2026.06.004_bib0465","doi-asserted-by":"crossref","first-page":"294","DOI":"10.3109\/14397595.2013.861333","article-title":"Neuromyelitis optica spectrum disorder complicated with Sjogren syndrome successfully treated with tocilizumab: a case report","volume":"26","author":"Komai","year":"2016","journal-title":"Mod Rheumatol"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0470","doi-asserted-by":"crossref","first-page":"e1100","DOI":"10.1212\/NXI.0000000000001100","article-title":"Interleukin-6 receptor blockade in treatment-refractory MOG-IgG-associated disease and neuromyelitis optica spectrum disorders","volume":"9","author":"Ringelstein","year":"2022","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0475","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1016\/S1474-4422(20)30070-3","article-title":"Safety and efficacy of tocilizumab versus azathioprine in highly relapsing neuromyelitis optica spectrum disorder (TANGO): an open-label, multicentre, randomised, phase 2 trial","volume":"19","author":"Zhang","year":"2020","journal-title":"Lancet Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2026.06.004_bib0480","doi-asserted-by":"crossref","first-page":"2114","DOI":"10.1056\/NEJMoa1901747","article-title":"Trial of satralizumab in neuromyelitis optica spectrum disorder","volume":"381","author":"Yamamura","year":"2019","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0485","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/S1474-4422(20)30078-8","article-title":"Safety and efficacy of satralizumab monotherapy in neuromyelitis optica spectrum disorder: a randomised, double-blind, multicentre, placebo-controlled phase 3 trial","volume":"19","author":"Traboulsee","year":"2020","journal-title":"Lancet Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0490","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1056\/NEJMoa1900866","article-title":"Eculizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"381","author":"Pittock","year":"2019","journal-title":"N Engl J Med"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0495","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1177\/13524585211038291","article-title":"Eculizumab monotherapy for NMOSD: data from PREVENT and its open-label extension","volume":"28","author":"Pittock","year":"2022","journal-title":"Mult Scler"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0500","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ana.26049","article-title":"Long-term safety and efficacy of eculizumab in aquaporin-4 IgG-positive NMOSD","volume":"89","author":"Wingerchuk","year":"2021","journal-title":"Ann Neurol"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0505","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.1002\/ana.26626","article-title":"Ravulizumab in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"93","author":"Pittock","year":"2023","journal-title":"Ann Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0510","series-title":"Infections, vaccinations et NMOSD\/MOGAD de l\u2019adulte\u00a0: recommandations du groupe NOMADMUS de la Soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques (SFSEP)","author":"Zephir","year":"2025"},{"key":"10.1016\/j.neurol.2026.06.004_bib0515","series-title":"Prophylaxie des infections invasives \u00e0 m\u00e9ningocoques chez les patients trait\u00e9s par ravulizumab ou \u00e9culizumab. Avis du 13 novembre 2020","year":"2020"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0520","doi-asserted-by":"crossref","first-page":"324","DOI":"10.1001\/jamaneurol.2013.5699","article-title":"Comparison of relapse and treatment failure rates among patients with neuromyelitis optica: multicenter study of treatment efficacy","volume":"71","author":"Mealy","year":"2014","journal-title":"JAMA Neurol"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0525","doi-asserted-by":"crossref","first-page":"2003","DOI":"10.1007\/s00415-017-8590-0","article-title":"Comparison of the efficacy of azathioprine and rituximab in neuromyelitis optica spectrum disorder: a randomized clinical trial","volume":"264","author":"Nikoo","year":"2017","journal-title":"J Neurol"},{"issue":"7","key":"10.1016\/j.neurol.2026.06.004_bib0530","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1212\/WNL.0b013e31822a2780","article-title":"Azathioprine: tolerability, efficacy, and predictors of benefit in neuromyelitis optica","volume":"77","author":"Costanzi","year":"2011","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurol.2026.06.004_bib0535","doi-asserted-by":"crossref","first-page":"1533","DOI":"10.1177\/1352458514525870","article-title":"Long-term efficacy, tolerability and retention rate of azathioprine in 103 aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder patients: a multicentre retrospective observational study from the UK","volume":"20","author":"Elsone","year":"2014","journal-title":"Mult Scler"},{"key":"10.1016\/j.neurol.2026.06.004_bib0540","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.msard.2018.12.038","article-title":"Clinical course, treatment responses and outcomes in Chinese paediatric neuromyelitis optica spectrum disorder","volume":"28","author":"Zhou","year":"2019","journal-title":"Mult Scler Relat Disord"},{"issue":"9","key":"10.1016\/j.neurol.2026.06.004_bib0545","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1001\/archneurol.2009.175","article-title":"Treatment of neuromyelitis optica with mycophenolate mofetil: retrospective analysis of 24 patients","volume":"66","author":"Jacob","year":"2009","journal-title":"Arch Neurol"},{"issue":"11","key":"10.1016\/j.neurol.2026.06.004_bib0550","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1001\/jamaneurol.2014.2057","article-title":"Mycophenolate mofetil in the treatment of neuromyelitis optica spectrum disorder","volume":"71","author":"Huh","year":"2014","journal-title":"JAMA Neurol"},{"issue":"10","key":"10.1016\/j.neurol.2026.06.004_bib0555","doi-asserted-by":"crossref","first-page":"1377","DOI":"10.1177\/1352458516678474","article-title":"Effectiveness of mycophenolate mofetil as first-line therapy in AQP4-IgG, MOG-IgG, and seronegative neuromyelitis optica spectrum disorders","volume":"23","author":"Montcuquet","year":"2017","journal-title":"Mult Scler"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0560","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12883-018-1056-x","article-title":"Dose effects of mycophenolate mofetil in Chinese patients with neuromyelitis optica spectrum disorders: a case series study","volume":"18","author":"Jiao","year":"2018","journal-title":"BMC Neurol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0565","doi-asserted-by":"crossref","first-page":"2066","DOI":"10.3389\/fimmu.2018.02066","article-title":"Low-dose mycophenolate mofetil for treatment of neuromyelitis optica spectrum disorders: a prospective multicenter study in South China","volume":"9","author":"Huang","year":"2018","journal-title":"Front Immunol"},{"issue":"4","key":"10.1016\/j.neurol.2026.06.004_bib0570","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1001\/archneurol.2010.322","article-title":"Efficacy and safety of mitoxantrone in patients with highly relapsing neuromyelitis optica","volume":"68","author":"Kim","year":"2011","journal-title":"Arch Neurol"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0575","doi-asserted-by":"crossref","first-page":"511","DOI":"10.1136\/jnnp-2012-303121","article-title":"Efficacy of mitoxantrone in neuromyelitis optica spectrum: clinical and neuroradiological study","volume":"84","author":"Cabre","year":"2013","journal-title":"J Neurol Neurosurg Psychiatry"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0580","doi-asserted-by":"crossref","first-page":"e200175","DOI":"10.1212\/NXI.0000000000200175","article-title":"Mitoxantrone in NMO spectrum disorder in a large multicenter cohort in French Caribbean","volume":"11","author":"Chaumont","year":"2024","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0585","doi-asserted-by":"crossref","first-page":"101235","DOI":"10.1016\/j.neurad.2024.101235","article-title":"MRI management of NMOSD and MOGAD: proposals from the French Expert Group NOMADMUS","volume":"52","author":"Durand-Dubief","year":"2025","journal-title":"J Neuroradiol"},{"key":"10.1016\/j.neurol.2026.06.004_bib0590","series-title":"Grossesse et NMOSD\u00a0: recommandations du groupe NOMADMUS de la Soci\u00e9t\u00e9 francophone de la scl\u00e9rose en plaques (SFSEP)","author":"Zephir","year":"2024"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0595","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1038\/s41582-020-0313-y","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: therapeutic considerations","volume":"16","author":"Mao-Draayer","year":"2020","journal-title":"Nat Rev Neurol"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0600","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1007\/s13167-018-0143-9","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: relapse-preventive measures and personalized treatment strategies","volume":"9","author":"Borisow","year":"2018","journal-title":"EPMA J"},{"key":"10.1016\/j.neurol.2026.06.004_bib0605","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.msard.2018.07.006","article-title":"Influences of pregnancy on neuromyelitis optica spectrum disorders and multiple sclerosis","volume":"25","author":"Tong","year":"2018","journal-title":"Mult Scler Relat Disord"},{"key":"10.1016\/j.neurol.2026.06.004_bib0610","doi-asserted-by":"crossref","DOI":"10.1177\/1756286418774973","article-title":"Tryptophan immunoadsorption during pregnancy and breastfeeding in patients with acute relapse of multiple sclerosis and neuromyelitis optica","volume":"11","author":"Hoffmann","year":"2018","journal-title":"Ther Adv Neurol Disord"},{"key":"10.1016\/j.neurol.2026.06.004_bib0615","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.jns.2018.01.040","article-title":"Study of the placentae of patients with neuromyelitis optica spectrum disorder","volume":"387","author":"Chang","year":"2018","journal-title":"J Neurol Sci"},{"issue":"14","key":"10.1016\/j.neurol.2026.06.004_bib0620","doi-asserted-by":"crossref","first-page":"1808","DOI":"10.1177\/1352458517740215","article-title":"Neuromyelitis optica spectrum disorders and pregnancy: Interactions and management","volume":"23","author":"Shosha","year":"2017","journal-title":"Mult Scler"},{"issue":"3","key":"10.1016\/j.neurol.2026.06.004_bib0625","doi-asserted-by":"crossref","first-page":"e339","DOI":"10.1212\/NXI.0000000000000339","article-title":"Female hormonal exposures and neuromyelitis optica symptom onset in a multicenter study","volume":"4","author":"Bove","year":"2017","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0630","doi-asserted-by":"crossref","first-page":"e288","DOI":"10.1212\/NXI.0000000000000288","article-title":"Immunology of neuromyelitis optica during pregnancy","volume":"3","author":"Davoudi","year":"2016","journal-title":"Neurol Neuroimmunol Neuroinflammation"},{"issue":"1","key":"10.1016\/j.neurol.2026.06.004_bib0635","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1212\/WNL.0000000000002208","article-title":"Pregnancy outcomes in aquaporin-4-positive neuromyelitis optica spectrum disorder","volume":"86","author":"Nour","year":"2016","journal-title":"Neurology"},{"issue":"11","key":"10.1016\/j.neurol.2026.06.004_bib0640","doi-asserted-by":"crossref","first-page":"1413","DOI":"10.1177\/1352458515583376","article-title":"Pregnancy-related relapse risk factors in women with anti-AQP4 antibody positivity and neuromyelitis optica spectrum disorder","volume":"22","author":"Shimizu","year":"2016","journal-title":"Mult Scler"},{"issue":"5","key":"10.1016\/j.neurol.2026.06.004_bib0645","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/nrneurol.2015.53","article-title":"Multiple sclerosis and pregnancy in the \u201ctreatment era\u201d","volume":"11","author":"Vukusic","year":"2015","journal-title":"Nat Rev Neurol"},{"issue":"22","key":"10.1016\/j.neurol.2026.06.004_bib0650","doi-asserted-by":"crossref","first-page":"2238","DOI":"10.1212\/WNL.0000000000004681","article-title":"High risk of postpartum relapses in neuromyelitis optica spectrum disorder","volume":"89","author":"Klawiter","year":"2017","journal-title":"Neurology"},{"issue":"6","key":"10.1016\/j.neurol.2026.06.004_bib0655","doi-asserted-by":"crossref","first-page":"2999","DOI":"10.4049\/jimmunol.1301483","article-title":"Neuromyelitis optica IgG causes placental inflammation and fetal death","volume":"191","author":"Saadoun","year":"2013","journal-title":"J Immunol"}],"container-title":["Revue Neurologique"],"original-title":[],"language":"fr","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872600562X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003537872600562X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:50:32Z","timestamp":1793217032000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003537872600562X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10]]},"references-count":131,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["S003537872600562X"],"URL":"https:\/\/doi.org\/10.1016\/j.neurol.2026.06.004","relation":{},"ISSN":["0035-3787"],"issn-type":[{"value":"0035-3787","type":"print"}],"subject":[],"published":{"date-parts":[[2026,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"French guidelines for the diagnosis and management of neuromyelitis optica spectrum disorder","name":"articletitle","label":"Article Title"},{"value":"Revue Neurologique","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neurol.2026.06.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Author(s). Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}]}}